Changmao Biochemical Engineering Company Limited reported no changes in either authorised or issued share capital for the month ended 31 July 2026, according to its latest submission to Hong Kong Exchanges and Clearing Limited dated 03 August 2026.
The company’s authorised share capital remained at RMB 52.97 million, comprising: • 183.70 million H shares, par value RMB 0.1 each. • 2.50 million domestic shares, par value RMB 0.1 each. • 343.50 million foreign shares, par value RMB 0.1 each.
Issued share capital was also unchanged, standing at 529.70 million ordinary shares, split as follows: • 183.70 million H shares listed on the Stock Exchange. • 2.50 million unlisted domestic shares. • 343.50 million unlisted foreign shares.
No treasury shares were held or cancelled, and no new share options, warrants, convertible securities, or other equity-linked instruments were issued during the period.
Management confirmed that the company met the Exchange’s minimum 25% public-float requirement for its H-share class as at 31 July 2026.